CONFERENCE UPDATE: EULAR 2022

Upadacitinib improves signs and symptoms of active nr-axSpA patients: The SELECT-AXIS 2 study

RHEUMATOLOGY
26 Jul 2022

Get access to our exclusive articles.
Related Articles

Upadacitinib: First-and-only oral JAK inhibitor approved for both AS and nr-axSpA

On October 21, 2022, the United States (US) Food and Drug Administration (FDA) approved upadacitinib for the treatment of patients with non-radiographic axial spondyloarthritis (nr-axSpA).1 The approval was based on the positive results of the SELECT-AXIS 2 phase 3 clinical trial which assessed the safety and efficacy of upadacitinib in adults with active nr-axSpA.1
RHEUMATOLOGY
12 Dec 2022